Clinical and Serological Follow-Up of 216 Patients with Hematological Malignancies after Vaccination with Pfizer-BioNT162b2 mRNA COVID-19 in a Real-World Study

Hematological malignancies (HMs) have heterogeneous serological responses after vaccination due to disease or treatment. The aim of this real-world study was to analyze it after Pfizer-BioNT162b2 mRNA vaccination in 216 patients followed up for 1 year. The first 43 patients had an initial follow-up...

Descripción completa

Detalles Bibliográficos
Autores principales: Rossi, Jean-François, Bonnet, Emmanuel, Castelli, Christel, Velensek, Marion, Wisniewski, Emma, Heraud, Sophie, Boustany, Rania, David, Céleste, Dinet, Jérôme, Sicard, Roland, Daures, Jean-Pierre, Bonifacy, Marion, Mousset, Lysiane, Goffart, Emmanuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10057553/
https://www.ncbi.nlm.nih.gov/pubmed/36992077
http://dx.doi.org/10.3390/vaccines11030493

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10057553/
https://www.ncbi.nlm.nih.gov/pubmed/36992077
http://dx.doi.org/10.3390/vaccines11030493

Ejemplares similares